United States-based developer, manufacturer and marketer of FDA-approved pharmaceuticals KVK Tech, Inc. announced on Wednesday that it has registered Lomaira™ (phentermine hydrochloride USP) 8mg tablets, CIV in Mexico.

The registration is the result of a strategic partnership with Productos Medix SA de CV, a company involved in pharmaceutical obesity products in Mexico. The licensing agreement provides Medix with a license for the manufacture, distribution, and marketing of Lomaira in Mexico.

Lomaira is an appetite suppressant available by prescription only and used for a short period of time for weight reduction in adults with an initial body mass index (BMI) of 30 or more or 27 or more with a weight-related condition such as controlled high blood pressure, diabetes, or high cholesterol.

Kiran Vepuri, KVK vice president of Business Development, said, 'We're thrilled for Medix to launch Lomaira in Mexico and help tackle the unmet needs in the global obesity epidemic. Obesity is not just an American problem and we aspire to help patients worldwide.'